Engaging Investor Conferences: Olema Oncology's Strategy Ahead
Olema Pharmaceuticals, Inc., known as Olema Oncology (NASDAQ: OLMA), is on the forefront of biopharmaceutical advancements. The company has announced an exciting opportunity for investors to connect with its leadership during several prominent upcoming investor conferences. These events allow Olema to showcase its commitment to developing innovative therapies that target breast cancer and improve patient outcomes.
Upcoming Conferences for Investors
Management from Olema will participate in two notable events aimed at bringing together industry leaders and investors:
Oppenheimer 35th Annual Healthcare Life Sciences Conference
The first conference is the 35th Annual Healthcare Life Sciences Conference, hosted by Oppenheimer. This event will take place in a virtual format on February 12, 2025, at 9:20 a.m. ET. Attendees can expect insightful discussions and an in-depth look at Olema's innovative approach to treating breast cancer.
Citi's 2025 Virtual Oncology Leadership Summit
Following the Oppenheimer conference, Olema will join Citi's 2025 Virtual Oncology Leadership Summit. Scheduled for February 20, 2025, at 10 a.m. ET, this fireside chat provides a platform for Olema to engage with investors while sharing valuable updates about their product pipeline.
Accessing Live Presentations
For those eager to hear from Olema's management, live webcasts of both presentations will be made available on the company's investor relations website. The webcasts will also be archived for at least 30 days, ensuring that interested parties can catch up on discussions at their convenience. These webcasts serve as an excellent opportunity for investors to gain insights into Olema's strategic direction and innovative therapies.
Commitment to Improving Patient Outcomes
Olema Oncology stands out for its commitment to transforming the standard of care for patients dealing with breast cancer. As a clinical-stage biopharmaceutical company, Olema is focused on advancing the development of targeted therapies. Their deep understanding of endocrine-driven cancers and the mechanisms of acquired resistance is crucial for their innovative approach.
Leading the Charge with Innovative Therapies
Among its promising developments is palazestrant (OP-1250), Olema's lead product candidate. This proprietary therapy acts as a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Presently, palazestrant is undergoing a Phase 3 clinical trial known as OPERA-01.
Exploring New Frontiers with KAT6 Inhibitor
Additionally, Olema is developing a potent KAT6 inhibitor, referred to as OP-3136. This innovative therapy is part of Olema's expanding pipeline, reflecting the company's commitment to providing better options for patients who currently have limited treatments available.
Company Overview
Headquartered in San Francisco, California, and with operations in Cambridge, Massachusetts, Olema Oncology is dedicated to improving the lives of patients with breast cancer. The company continually seeks new ways to innovate and expand its therapeutic offerings. More information about Olema and its innovative work can be found on their corporate website.
Contact Information
For media inquiries or further information, Courtney O’Konek, the Vice President of Corporate Communications, can be reached at the company’s corporate communications email.
Frequently Asked Questions
What is Olema Oncology's primary focus?
Olema Oncology focuses on discovering and developing targeted therapies for breast cancer and endocrine-driven tumors.
When will Olema participate in their next investor conference?
Olema will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.
How can I access the live webcasts from Olema’s presentations?
The webcasts can be accessed through Olema’s investor relations website, where they will also be archived for future viewing.
What is palazestrant (OP-1250)?
Palazestrant is Olema's lead product candidate, acting as a complete estrogen receptor antagonist and selective estrogen receptor degrader currently under Phase 3 clinical trial.
How can I contact Olema Oncology for more information?
You can reach out to Courtney O’Konek, Vice President of Corporate Communications, through the media contact email provided on Olema’s website.
